Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05547165

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment.

There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.

Recruiting

Interested in participating?

Request Info

Key information

Age range

7 day–32 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • EPIs born between 22-weeks+0 days (220/7 wks) and 27-weeks+6 days (276/7 wks) gestation, inclusive
  • Admitted to a study NICU
  • Birth weight ≥700-grams
  • Mechanically ventilated at time of consent and randomization
  • HSPDA ("PDA Score" ≥6) noted on echocardiogram (ECHO)
  • Randomization is able to be performed within 5 days of the qualifying ECHO and when infant is 7-32 days postnatal

Exclusion criteria

Clinical Exclusion Criteria

  • Life-threatening congenital defects (including congenital heart disease such as aortic coarctation or pulmonary artery stenosis). PDA and small atrial/ventricular septal defects are permitted;
  • Congenital lung abnormalities, (e.g. restrictive lung disease);
  • Pharyngeal or airway anomalies (tracheal stenosis, choanal atresia);
  • Treatment for acute abdominal process (e.g., necrotizing enterocolitis);
  • Infants with planned surgery;
  • Active infection requiring treatment;
  • Chromosomal defects (e.g., Trisomy 18);
  • Neuromuscular disorders;
  • Infants whose parents have chosen to allow natural death (do not resuscitate order) or for whom limitation of intensive care treatment is being considered (e.g. severe intraventricular hemorrhage)
  • Physician deems that the infant would not be a Percutaneous PDA Closure candidate due to clinical instability; however, if the infant's clinical status improves before 30-days postnatal and all inclusion criteria are still met, then the infant may be enrolled.

ECHO-based Exclusion Criteria

  • Pulmonary hypertension (defined by ductal right to left shunting for >33% of the cardiac cycle) in which early PDA closure may increase right ventricular afterload and compromise pulmonary and systemic blood flow;
  • Evidence of cardiac thrombus that might interfere with device placement;
  • PDA diameter larger than 4 mm at the narrowest portion (consistent with FDA-approved instructions for Piccolo™ device use).
  • PDA length smaller than 3 mm (consistent with FDA-approved instructions for Piccolo™ device use).
  • PDA that does not meet inclusion requirements ("PDA Score" <6).* * If a potential participant is found to have a PDA meeting eligibility requirements on a subsequent ECHO during the required period of 7 - 30 postnatal days of age, they may then be declared eligible to participate and enrolled, provided all other inclusion criteria are met and exclusion criteria are not met.

Other Exclusion Criteria

  • Parents or legal guardian do not speak English or Spanish

Treatment and study plan

Percutaneous Patent Ductus Arteriosus Closure (PPC)

Device

Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.

Responsive Management Intervention

Combination Product

Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.

Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP).

Echocardiogram, cardiac

Diagnostic Test

An echocardiogram, also known as "ECHO", is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions.

Primary outcomes

  1. Number of days free of ventilatory support requirement (ventilator-free days; VFDs)

    Time frame: 30 days post-randomization

    Ventilator free days (VFDs) are defined as the number of days that a subject is alive and free from mechanical ventilatory support. VFDs are an established respiratory outcome measure in pediatric clinical trials, and are a strong predictor of short-term and longer-term oucomes, including length of neonatal intensive care unit (NICU) stay, morbidities, and mortality.

Secondary outcomes

  1. Positive-pressure dependency or death

    Time frame: 36 weeks post-menstrual age

    A composite outcome measure (yes/no), positive pressure dependency at 36 weeks post-menstrual age (PMA) is an indicator of chronic lung disease (CLD), the most common and serious respiratory complication of prematurity. Both invasive and non-invasive positive pressure ventilation at 36 weeks PMA is associated with long-term respiratory and neurodevelopmental impairment.

  2. Diagnosis of pulmonary hypertension or death

    Time frame: 36 weeks post-menstrual age

    A compositve binary outcome measure (yes/no), diagnosis of pulmonary hypertension will be determined by cardiac echocardiogram at 36 weeks post-menstrual age. Diagnosis of pulmonary hypertension is an indicator of increased pulmonary vasculature resistance, a marker for increased morbidity and mortality among infants with chronic lung disease.

  3. Total days on mechanical ventilation

    Time frame: 4 months corrected age

    The total number of days (continuous variable) a study subject requires any use of invasive mechanical ventilatory support within a 24-hour calendar day.

  4. Days requiring positive-pressure assisted breathing

    Time frame: Randomization through 4 months corrected age

    The sum of days the study subject requires either invasive or non-invasive positive pressure assisted ventilation within a 24 hour calendar day.

  5. Days on supplemental oxygen

    Time frame: Randomization through 4 months corrected age

    Total number of days the study subject requires supplemental oxygen. The subject may be on either invasive or non-invasive ventilatory support during this time. The subject must be free from supplemental oxygen use for a period of at least 24 hours to interrupt or cease counting.

  6. Time to death

    Time frame: Randomization through 4 months corrected age

    A continuous measure, in days, of the time from a study subject's randomization to expiration, if this occurs.

  7. Diagnosis of cardiac dysfunction

    Time frame: 36 weeks post-menstrual age

    A diagnosis of left-ventricular output by echocardiography (ECHO) at 36 weeks post-menstrual age.

  8. Abnormal cardiac remodeling

    Time frame: 36 weeks post-menstrual age

    Finding of left-ventricular end-diastolic volume (LV EDV) >97% on echocardiography (ECHO) at 36 weeks post-menstrual age.

  9. General Movements Assessment (GMA)

    Time frame: 34 - 36 weeks post-menstrual age

    The General Movements Assessment (GMA) is a standardized video-based neurological exam to evaluate the presence of "fidgety" versus "absent fidgety" and "cramped-synchronized" versus "non cramped-synchronized" movement patterns at 34 - 36 weeks post-menstrual age. It is used to assist in the diagnosis of impaired motor neurodevelopment and cerebral palsy.

  10. Need for rescue intervention

    Time frame: Randomization through 4 months corrected age

    Recording of incidence of need for study subjects randomized to Responsive Management to undergo Percutaneous Patent Ductus Arteriosus Closure (PPC) due to decline in health status.

  11. Hammersmith Neonatal Neurological Examination (HNNE)

    Time frame: 34 - 36 weeks post-menstrual age

    The HNNE is a standardized neurological examination of 34 items to evaluate tone, motor patterns, spontaneous movements, reflexes, visual and auditory attention, and behavior.

  12. Hammersmith Infant Neurological Examination (HINE)

    Time frame: 3 - 4 months of corrected age

    The HINE is similar to the HNNE, used to assess neurological function at 3 - 24 months of age, including cranial nerve function, movements, reflexes, protective reactions and behavior, and age-dependent evaluation of gross and fine-motor function.

  13. Infant/Toddler Sensory Profile (Low Registration Domain)

    Time frame: 3 - 4 months of corrected age

    Caregiver questionnaire responses to determine if their infant appropriately processes and responds to environmental stimuli, versus missing or taking longer to respond ("Low Registration"). There are 13 items with scores of 13 - 65 possible; scores of 42 - 51 are considered "Typical performance".

  14. Infant/Toddler Sensory Profile (Sensation Seeking Domain)

    Time frame: 3 - 4 months of corrected age

    Caregiver questionnaire responses to determine if their infant is hyposensitive, seeking additional sensory stimulation. There are 6 items with scores of 6 - 30 possible; scores of 7 - 15 are considered "Typical performance".

  15. Infant/Toddler Sensory Profile (Sensory Sensitivity Domain)

    Time frame: 3 - 4 months of corrected age

    Caregiver questionnaire responses to determine if their infant responds readily to sensory stimulation, without actively avoiding it. There are 12 items with scores of 12 - 60 possible; scores of 45 - 57 are considered "Typical performance)

  16. Infant/Toddler Sensory Profile (Sensation Avoiding Domain)

    Time frame: 3 - 4 months of corrected age

    Caregiver questionnaire responses to determine if their infant avoids sensory stimulation. There are 5 items with scores of 5 - 25 possible; scores of 19 - 25 are considered "Typical performance".

  17. Infant/Toddler Sensory Profile (Low Threshold Domain)

    Time frame: 3 - 4 months of corrected age

    Caregiver questionnaire responses which are the sum of the Sensory Sensitivity and Sensation Avoiding domains). Summed scores of 15 - 85 are possible; summed scores of 64 - 81 are considered "Typical performance".

  18. Baby Care Questionnaire (BCQ)

    Time frame: 3 - 4 months of corrected age

    The BCQ is another caregiver-based questionnaire for parental perspectives of an infant's feeding and sleeping habits. It is used as an evaluation of a parent's reliance upon structure / routines and attunement (dependence upon infant's cues).

  19. Mother-Infant Bonding Scale (MIBS)

    Time frame: 3 - 4 months of corrected age

    The MIBS is an 8-item questionnaire to evaluate a mother's bondedness towards her infant. Responses are scored from 0 to 3 for each item, with a total possible range of 0 - 24. Lower scores indicate more favorable outcomes for mother-infant bondedness, whereas higher scores indicate the potential for difficulties.

  20. Type and incidence of any adverse event

    Time frame: 3 - 4 months of corrected age

    Reporting of type and frequency of any adverse event that occurs during percutaneous closure procedures, and post-procedurally that may be related to the intervention.

  21. Type and incidence of serious adverse event

    Time frame: 3 - 4 months of corrected age

    Reporting of type and frequency of any serious adverse event (e.g., potentially life-threatening change in status) that occurs during percutaneous closure procedures, and post-procedurally that may be related to the intervention.

Other outcomes

  1. Determine whether neurodevelopment at 3-4 months CA is mediated by improved neurodevelopmental profiles at 34-36 weeks PMA.

    Time frame: 34-36 weeks post-menstrual age and 3 - 4 months corrected age

    Analysis of HNNE / HINE scores to determine if neurodevelopmental evaluation scores conducted at 34 - 36 weeks post-menstrual age mediate outcomes at 3 - 4 months corrected age

  2. Evaluation of effect modifiers on primary and secondary outcomes

    Time frame: Birth to 4 months of corrected age

    Examination of the homogeneity of the effect of HSPDA on the primary and secondary outcomes will be carried out in statistical analyses using stratification variables (e.g., gender, gestational age, etc.) and characteristics not balanced through random assignment, if any such imbalances are found.

Study contacts

Contact information is provided by the study sponsor or research team.

Carl H Backes

CONTACT

[email protected]

16143556729

Jonathan Slaughter

CONTACT

[email protected]

16143556643

Sponsors and collaborators

Lead sponsor

Nationwide Children's Hospital

Other

Collaborators

  • Abbott
  • Cedars-Sinai Medical Center
  • Children's Hospital Los Angeles
  • Dartmouth College
  • Emory University
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institutes of Health (NIH)
  • University of Bristol
  • University of Iowa
  • University of Pittsburgh

Registry information

Acronym: PIVOTAL

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Sep 21, 2022
Registry last updated
Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.